ITGAL and pulmonary fibrosis: Unfortunately, due to unforeseen circumstances we were unable to complete our own in vivo experiments with LFA 878, but further exploration of the therapeutic importance of specific I domain, LFA-1 inhibitors, such as LFA 878, in a model of bleomycin induced pulmonary fibrosis may reveal another important target for the management of this disease.